Related Experiment Video
Updated: Jun 13, 2025
03:40
Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
Published on: January 17, 2025
270
Bivalirudin in Extracorporeal Membrane Oxygenation.
Sabrina Dunham1, Patrick M Wieruszewski2,3, James E Gerrald4
1Department of Pharmacy Services, University of Michigan Health, Ann Arbor, MI.
Journal of Cardiovascular Pharmacology
|September 11, 2024
Summary
Bivalirudin, a direct thrombin inhibitor, may offer improved safety and efficacy in extracorporeal membrane oxygenation (ECMO) compared to heparin. This review highlights bivalirudin
Area of Science:
- Cardiovascular Medicine
- Hematology
- Critical Care Medicine
Background:
- Extracorporeal membrane oxygenation (ECMO) is vital for refractory cardiac/pulmonary failure.
- Bleeding and thrombosis are significant complications requiring careful anticoagulation management.
- Heparin, commonly used, has limitations including heparin-induced thrombocytopenia and resistance.
Purpose of the Study:
- To review the evidence for bivalirudin use in ECMO.
- To compare bivalirudin's safety and efficacy against heparin.
- To discuss practical considerations for bivalirudin implementation in ECMO.
Main Methods:
- Literature review of studies on bivalirudin in ECMO.
- Analysis of outcomes related to thrombosis, bleeding, and anticoagulation.
- Discussion of clinical considerations and challenges.
Main Results:
- Bivalirudin shows favorable outcomes in reducing circuit thrombosis and bleeding events.
- Improved dosing reliability and reduced blood product utilization observed with bivalirudin.
- Positive trends in ECMO decannulation success and patient survival noted.
Conclusions:
- Bivalirudin presents a potentially advantageous alternative to heparin for ECMO anticoagulation.
- It may simplify ECMO management by improving safety and reliability.
- Further investigation into specific clinical scenarios is warranted.
